Introduction
Patient-reported outcomes (PROs) are increasingly being used. Patients' reports of symptoms, function and healthrelated quality of life (HRQL) or overall quality of life (QoL) can provide important information about the impact that health problems and related treatments have on patients' lives [1, 2] . These terms are often used interchangeably and for the remainder of this paper we will use the term HRQL. Typically, PROs are used to study outcomes at the group level. However, in some prostate cancer centres, a formal tool for the collection of PROs has been implemented in routine clinical practice to monitor outcomes in individual patients after radical surgery [3] .
In the UK,~10% of men newly diagnosed with prostate cancer have a radical prostatectomy (RP) [4] . In addition to cancer cure, surgeons consider the absence of side-effects, such as urinary incontinence and erectile dysfunction, as important indicators of the success of the surgery. Men themselves are interested in a wider range of outcomes [5] , including anxiety and distress, social interactions and intimate relations [6] , feelings of masculinity and self-esteem [7] . It is therefore important that both developers and users of PRO questionnaires for men diagnosed with prostate cancer are clear about what the questionnaire is supposed to measure, whether the questionnaire actually measures these concepts, and how well it does so. Several reviews have evaluated the scientific or psychometric properties of existing PRO questionnaires that are being used for patients diagnosed with prostate cancer [8] [9] [10] . In general, these reviews have used well-established guidelines and criteria based on classical test theory to evaluate the robustness of existing instruments [11] [12] [13] . The performance of these instruments is often expressed in terms of reliability (the extent to which an instrument is free from error), validity (the extent to which it measures what it aims to measure), and responsiveness (the ability to detect clinically important changes over time). However, none of the existing reviews has included a critical review of the conceptual content of existing instruments or evaluated the extent to which these instruments are fit to monitor outcomes in individual patients.
To evaluate instruments' fitness to measure outcomes at the individual level, modern psychometric approaches are now often used, such as Rasch measurement theory and item response theory [14] [15] [16] . Scores derived from these approaches have several advantages over methods based on classical test theory: they are truly interval scores, meaning that there is an equal distance between each of the values on the scale (as opposed to ordinal scores, where values are in rank order but the distance between any two values may not be equal), invariant (independent of both the distribution of items and the distribution of the sample), and potentially appropriate for use in individual patients.
Inconsistency about how HRQL is defined adds to the complexity of evaluating PRO questionnaires that claim to measure these constructs. Although there is no universal definition of HRQL, it is generally agreed that it is multidimensional and subjective [17] [18] [19] . That is, HRQL focuses on the perceived impact (from the patient's perspective) of physical, mental and social domains of health. HRQL is therefore not usually concerned with how much of a symptom a patient has, but rather to what extent the patient is 'bothered by' or 'concerned about' that symptom. In addition, Wilson and Cleary [20] have provided a conceptual framework that places HRQL in the wider context of health outcomes and suggests how HRQL is related to other health outcomes widely used in clinical and health services research. They distinguish five levels of outcome: 'biological and physiological variables', 'symptom status', 'functional status', 'general health perceptions', and 'overall QoL'. These five outcomes are considered to be separate constructs that are causally related (e.g. 'symptom status' will affect 'functional status', which in turn is likely to affect HRQL). It is important to note that the 'overall QoL', construct in the Wilson and Cleary framework, should reflect individuals' subjective perception of how happy or satisfied they are with their life as a whole.
To address the shortcomings of previous reviews, and to evaluate whether the HRQL outcomes that are important to men are being assessed, we carried out a review of the existing psychometric reviews of prostate cancer-specific instruments developed to collect PROs. Our aims were to: (i) critically review the conceptual content of available PRO questionnaires used in men having RP, (ii) psychometrically evaluate each instrument, and (iii) determine the extent to which each instrument is appropriate for use in individual patients. We used this review-of-reviews to identify the original development articles and we applied the Wilson and Cleary framework as the basis for a critical appraisal of the instruments' conceptual content [20] . We also summarised the available psychometric evidence for each instrument and assessed the extent to which each instrument is appropriate for use in individual patients.
Materials and Methods

Search Strategy
We searched the PubMed database from its beginning to June 2015 to identify psychometric reviews of prostate cancerspecific PRO questionnaires. We searched PubMed using the following search strategy: ('quality of life' OR 'QoL' OR 'HRQL' OR 'symptom' OR 'function' OR 'disability' OR 'patient reported outcome') AND ('prostate') AND ('instrument' OR 'measure' OR 'questionnaire'), limited by 'review' and 'systematic review'.
To identify additional reviews, we searched the Reports and Publications database of the University of Oxford PatientReported Outcomes Measurement Group [21] . We also searched the website of the International Consortium for Health Outcomes Measurement (ICHOM) for reports of recommendations on prostate cancer-specific PROs [22] .
Instrument Selection
From the identified review papers, we compiled a list of instruments recommended by the reviewers following psychometric assessment, and located the original development articles. We excluded instruments developed in languages other than English, generic cancer-related instruments, instruments that were designed to capture utilities (i.e. quantitative measures of individuals' preferences for specific health states), instruments not developed for use in patients with prostate cancer, and instruments specifically designed to be used in men who had prostate cancer treatments other than RP. Single question assessments were also excluded.
Data extraction and Appraisal
We identified the original development article(s) for each instrument, and extracted data for each instrument, using a standard data extraction form derived from Smith et al. [23] . The criteria used for this appraisal are described in Table 1 and based on well-established classical psychometric criteria [11, 12, 13] . We chose these guidelines because they were specifically focused on the criteria for the psychometric properties that an instrument must have, rather than the quality of the paper reporting the instrument development, which the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) guidelines address [24] . To assess content validity, we also undertook a conceptual review of each of the identified instruments using the five levels of outcome included in the Wilson and Cleary framework [20] . We used this framework as a guide to High correlation between the scale and the criterion measure.
Predictive validity
Evidence that the scale predicts a 'gold standard' criterion that is measured in the future; assessed on the basis of correlations between the scale and the criterion measure.
High correlation between the scale and the criterion measure. 4.3 Construct validity 4.3.1 Within-scale analyses Evidence that a single entity (construct) is being measured and that items can be combined to form a summary score; assessed on the basis of evidence of good internal consistency and correlations between scale scores (which purport to measure related aspects of the construct).
Internal consistency (Cronbach's a) ≥0.70. Moderate to high correlations between scale scores.
Analyses against external criteria 4.3.2.1 Convergent validity
Evidence that the scale is correlated with other instruments measuring the same or similar constructs; assessed on the basis of correlations between the instrument and other similar instruments.
Correlations are expected to vary according to the degree of similarity between the constructs that are being measured by each instrument. Specific hypotheses are formulated and predictions tested on the basis of correlations.
Discriminant validity
Evidence that the scale is not correlated with instruments measuring different constructs; assessed on the basis of correlations with instruments measuring different constructs.
Low correlations between the instrument and instruments measuring different constructs.
Known groups differences
The ability of a scale to differentiate known groups; assessed by comparing scores for subgroups who are expected to differ on the construct being measured.
Significant differences between known groups or difference of expected magnitude.
Hypothesis testing
The extent to which the scale confirms pre-defined hypotheses regarding expected associations or lack of association with external factors, such as patient characteristics.
Significant moderate to high correlations, or significant associations in the expected direction. Expected lack of association confirmed.
Responsiveness
The ability of a scale to detect clinically important change over time; assessed by comparing scores before and after an intervention of known efficacy (on the basis of various methods including t-tests, effect sizes, standardised response means, or responsiveness statistics).
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© 2017 The Authors BJU International © 2017 BJU International compare the items of each instrument with the construct that each instrument claimed to measure. For example, if an instrument claimed to measure HRQL, we expected items to reflect the subjectively perceived impact of physical, mental and social domains of health rather than the objective level of physical, mental or social health. That is, an item measuring HRQL would ask about the extent to which a man is concerned or bothered by his symptoms rather than the extent to which he has symptoms. Two authors (S.C.S., E.P.) reviewed each instrument using the standard extraction form. These two authors completed the review independently and then discussed any discrepancies until reaching consensus.
Results
The literature search generated 450 review papers; 447 articles were identified via PubMed, while three articles were identified from the remaining sources. After removing duplicates, 448 abstracts were screened and 33 full-text articles reviewed. Four papers presenting the results of psychometric reviews [8] [9] [10] 25] were identified and one paper describing recommendations by the ICHOM [22] [26] [27] [28] [29] [30] [31] [32] [33] [34] . The FACT-P [32] and EORTC QLQ-C30 [35] are generic cancer-related QoL instruments with an additional prostate cancer-specific module. The prostate cancer-specific module of EORTC QLQ-C30 is known as EORTC QLQ-PR25 [33] . We evaluated only the prostate cancer-specific subscales for these two PRO questionnaires. An instrument, developed by the Memorial Sloan Kettering Cancer Center (New York, USA), known as STAR (Symptom Tracking and Reporting) [3] , to monitor PROs after RP in routine clinical practice is also included in this review because it is widely used and was developed specifically for repeat use in men having RP. Therefore, seven instruments are described in Table 2 [3, [26] [27] [28] [29] [30] [31] [32] [33] [34] .
Conceptual Review
Our conceptual review addressed the content validity of each instrument in terms of the extent to which the items in each instrument reflected the construct that the developers claimed the instrument measured. The developers of six of the seven identified instruments themselves used the terms 'HRQL' or 'overall QoL' to describe what their instruments measured (EPIC-26, EPIC-50, UCLA-PCI, EORTC QLQ-PR25, and PC-QoL). 1 The remaining instrument, STAR, aimed to measure 'functional recovery' after RP.
The results of our conceptual review are shown in Figs 2-8. For each instrument, we allocated each item (question) to one of Wilson and Cleary's levels of outcome (i.e. 'biological and physiological variables', 'symptom status', 'functional status', 'general health perceptions', and 'overall QoL'). This allowed us to critique the conceptual content of each instrument by determining which level of outcome each item represented. None of the seven instruments include items related to the Wilson and Cleary outcome level labelled as 'biological and physiological variables'. All instruments include items related to 'symptom status' or 'functional status', particularly sexual and urinary problems, and all instruments except EPIC-26 include items about bowel problems. In addition, EPIC-50 and EORTC QLQ-PR25 also include hormonal symptoms and FACT-P (PCS) includes other symptoms and functional problems, such as weight loss, appetite, and pain.
STAR is the only instrument that includes an item related to 'general health perceptions', asking about the overall feeling related to the current state of health.
All instruments included some items that can be labelled as 'QoL'. Across all instruments these are mostly focused on the subjective impact of physical health, with fewer items representing the perceived impact of mental health. The EPIC-26, EPIC-50 and PC-QoL include the most items that can be labelled as 'QoL'. In general, most of these items reflect the subjective impact of physical aspects of health (e.g. the extent to which dripping or leaking urine is perceived as a problem or the extent to which changes in body weight are perceived as a problem). The PC-QoL also includes items that reflect the impact of mental aspects of health (e.g. concern/ anxiety about treatment, recurrence, and quality of care). However, items reflecting the subjective impact of social aspects of health were less common. Only PC-QoL includes an item about worry arising from being unable to please a partner sexually, an aspect of social health.
In the items that could be labelled as Wilson and Cleary's term 'overall QoL' (although this was often described as HRQL by developers of the questionnaires) in the remaining instruments, there was a similar predominance of items asking about the subjective impact of physical aspects of health. The HRQL 
Sexual function
Ability to penetrate partner
Bowel function
Bowel problems or bowel pain making it difficult to enjoy life
Overall bowel habits problem
Bowel QoL
Overall urinary function problem
Urinary QoL
Overall feeling about current state of health
Overall health perception
Difficulty to maintain erection to complete intercourse items in EORTC QLQ-PR25 include three items about the subjective impact of physical health (e.g. the extent to which weight gain, weight loss and incontinence aids have been a problem) and one about the impact of mental health (feeling less masculine). Similarly, the HRQL items in the UCLA-PCI include six items about the subjective impact of aspects of physical health (e.g. the extent to which ripping, leakage and overall urinary function have been a problem, distress caused by bowel movements and the extent to which bowel habits and getting and maintaining an erection have been a problem) and one item about the impact of mental health (feeling less masculine as a result of treatment). STAR and FACT-P PCS have the narrowest HRQL focus. The STAR includes two HRQL items, both assessing the subjective impact of aspects of physical health (the extent to which urinary and bowel function are a problem). The FACT-P PCS includes three HRQL items, of which two assess the subjective impact of physical aspects of health (satisfaction with comfort level and levels of pain) and one assesses the impact of mental health (ability to feel like a man).
Psychometric Appraisal
The detailed psychometric review of the seven identified instruments, based on their development papers is described below, and the results of their psychometric appraisal is shown in Table 3 [3, [26] [27] [28] [29] [30] [31] [32] [33] [34] . Overall, the psychometric evidence supporting the instruments was patchy and variable in quality.
Classical Test Theory
Evidence supporting instrument acceptability was weak for all instruments except EPIC-50, with high floor and/or ceiling effects across most instruments. All instruments had evidence supporting their reliability, although this evidence was weak for STAR and FACT-P PCS. These scales (together with the EORTC QLQ-PR25) only assessed one type of reliability (internal consistency).
For all instruments there was evidence of at least one other form of validity. This evidence was weakest for FACT-P PCS which only had weak evidence for known groups differences. Validity evidence was moderately strong for the other instruments, across a range of different types of validity.
Lastly, evidence regarding the responsiveness of all instruments was very limited, which makes it impossible to assess the instruments' ability to detect clinically important differences in HRQL in relation to treatment over time. 
Urinary obstruction / irritation
Dripping or leaking urine problem
Urinary incontinence
Urinary QoL
Erections when wanted
Quality of erections
Sexual function
Urinary control
Leaking urine
Urinary incontinence symptoms
Ability to reach orgasm (climax)
Ability to have an erection
Sexual symptoms
The ability of the individual to perform particular defined tasks. The function of cells, organs etc.
Level of sexual desire
Urinary symptoms
Overall ability to function sexually
Overall bowel habits problem
Getting and maintaining an erection problem
Sexual QoL Distress caused by bowel movements
Bowel QoL
Overall urinary function problem Urine leakage interfering with sexual activity problem Dripping urine or wetting pants problem
Urinary QoL
Frequency of sexual intercourse Erections when wanted
Quality of erections
Sexual function
Crampy pain in abdomen / pelvis Loose stools
Rectal urgency
Bowel symptoms
Pads or adult diapers used per day 
Additional symptoms
The ability of the individual to perform particular defined tasks. 
Modern Test Theory
No instrument was developed or subsequently analysed using item response theory or Rasch measurement theory.
Conclusion
We found that the developers of most of the seven identified prostate cancer-specific PROs claim that these instruments measure 'HRQL' or 'overall QoL', but their items strongly focus on urinary, sexual and bowel symptoms and function. All questionnaires include some items with a more subjective element to determine the extent to which men are concerned or bothered by a particular symptom. However, no instrument includes the full range of items necessary to represent HRQL in terms of the subjective impact of physical, mental, and social aspects of prostate cancer. These gaps not only compromise the content validity of the six instruments that claim to measure HRQL but they also affect the interpretation of the scores and their suitability for use in research and service evaluation. This means that in clinical practice the true impact of prostate cancer treatment is not reflected in the current outcomes. The currently available instruments do not measure the range of outcomes that are important to men.
Generally, evidence of reliability and validity is incomplete for all instruments. The EPIC-50, EPIC-26, UCLA-PCI and PCQoL have most evidence for robust psychometric properties. Of these, the EPIC-26 has the advantage that it is well-used and has comparable psychometric properties to the EPIC-50, but is considerably shorter. However, as none of the instruments has evidence of responsiveness, it is impossible to draw any conclusion about whether they are sensitive to clinically meaningful change. None of the instruments has been evaluated using modern psychometric methods and consequently we have no evidence about how well they work at the individual patient level.
Although only the PC-QoL had content validity as a measure of HRQL (i.e. it included items reflecting the perceived impact of physical, mental and social aspects of health), closer inspection of the items across all of the instruments suggests that most reflect the recognised side-effects of RP. However, the relatively narrow focus and dearth of items reflecting patients' subjective feelings about the impact of physical, mental and social aspects of health means that they may not reflect all the outcomes that are important to patients. There is a need for greater qualitative understanding of HRQL for men with prostate cancer and to develop questionnaire items that reflect this. Additionally, further psychometric 
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Our present findings are limited by the fact that we used the instruments that were recommended by other reviews. The five reviews overlapped in their recommendations, especially for EPIC-50, EPIC-26 and UCLA-PCI. As these recommendations are often the basis of how researchers and practitioners choose instruments, it is an appropriate shortlist for further critique. The authors of each review used slightly different psychometric criteria to reach their conclusions, but there was also much similarity in the criteria that were used.
In addition, the review of questionnaire items and their conceptual content involves a degree of judgement. We have made our definitions explicit and based them on the widely available and often cited literature in this area. The categorisation of each item was undertaken by two of the authors and later also reviewed by the remaining authors.
The results of our present review, and especially the evaluation of conceptual content, suggest that the available PROs offer a limited evaluation of the outcomes after RP that are relevant to men with prostate cancer. There are gaps in content and also inadequate evidence of reliability, validity, and responsiveness of the existing instruments.
In conclusion, several instruments provide the basis of measures of urinary symptoms and/or sexual function that could potentially be used at the group level. Although the focus on symptoms and functional outcomes is of interest to both clinicians and patients, there are other aspects of HRQL that need to be explored as important outcomes for men receiving RP for prostate cancer. As yet, there is no formal evidence to support the appropriateness of the questionnaires for use at the individual level.
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